Washington Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
CI
APM
HIIFS
Washington Capital Management's XBI Position: Q2 2022 in Review
Washington Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2022, closing a stake of 5,335 shares — an estimated $480K sold.
Washington Capital Management first reported a position in XBI in Q1 2022 and held it in 1 quarter. The position peaked at $480K in Q1 2022. 706 funds tracked by Wall St. Rank hold XBI as of Q2 2022.
- Washington Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2022 after selling out during the quarter.
- Washington Capital Management sold 5,335 State Street SPDR S&P Biotech ETF shares in Q2 2022, an estimated $480K.
- Washington Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2022 and held it in 1 quarter.
- Washington Capital Management's State Street SPDR S&P Biotech ETF position peaked at $480K in Q1 2022.
- 706 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2022.
Based on Washington Capital Management's 13F filing for Q2 2022, filed 15 Jul 2022.